Phathom Pharmaceuticals Inc. (PHAT)
NASDAQ: PHATHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PHAT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $378.82M
- Forward P/E
- 5.18
- EPS (TTM)
- -$1.01
- Dividend yield
- None
- 52-week range
- 4.62 – 18.31
- Day range
- 4.62 – 5.15
- Volume / Avg
- 1.33M / 1.45M
- Beta
- —
- Shares outstanding
- 81.29M
52-week range
PHAT stock today
Phathom Pharmaceuticals (PHAT) closed at $4.66 on Nov 20, down 8.27% (-$0.42), versus the S&P 500's 3.70% decline. Shares are 74.5% below their 52-week high of $18.31, set on Dec 23, 2025 and 1.0% above the 52-week low of $4.62, near the bottom of the past year's range. PHAT is down 71.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.9%.
Phathom Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Phathom Pharmaceuticals
Company profilePhathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven L. Basta M.B.A.
- Headquarters
- Florham Park, NJ
- Employees
- 371
- IPO year
- 2019
- Website
- phathompharma.com
Financial highlights
Full financialsIn fiscal 2025, Phathom Pharmaceuticals generated $175.1 million in revenue, up 216.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Phathom Pharmaceuticals reported a net loss of $221.2 million, compared with a loss of $334.3 million a year earlier. Gross margin was 87.1% (up from 85.6%) and operating margin -91.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $175.11M | $55.25M | $682.00K | $0 | — |
| Growth | +216.93% | +8001.47% | — | — | — |
| Net income | $-221.25M | $-334.33M | $-201.59M | $-197.72M | $-143.88M |
| EPS (diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$19.65+321.67%
- Strong buy 2
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.16 vs $-0.01
- Surprise
- -1500.00%
PHAT news
All PHAT news- Phathom Pharmaceuticals, Inc. Reports Resignation of Vice President, Finance Robert Breedlove, Effective December 4, 2026Nasdaq
- Phathom: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Phathom Pharmaceuticals to Participate in November Investor ConferencesGlobeNewswire
- Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRxGlobeNewswire
- Phathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12MSeeking Alpha
- Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesNasdaqPHAT, ROIV
- Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- FDA Establishes Public Docket FDA-2026-N-13038 Following Challenge to VOQUEZNA ExclusivityNasdaq
Phathom Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs PHAT |
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs PHAT |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs PHAT |
| OCSOculis Holding AG | 7.06 | -5.11% | $393.35M | vs PHAT |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs PHAT |
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs PHAT |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs PHAT |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs PHAT |
Indexes, lists and sector
Phathom Pharmaceuticals stock FAQ
What is Phathom Pharmaceuticals's stock price today?
PHAT last traded at $4.66 as of Nov 20, 4:00 PM EST, down 8.27% on the day. Prices are delayed at least 15 minutes.
Who is Phathom Pharmaceuticals's CEO?
Mr. Steven L. Basta M.B.A. is the chief executive officer of Phathom Pharmaceuticals Inc., which has about 371 employees.
What is the PHAT 52-week high?
The 52-week high for PHAT is $18.31 and the 52-week low is $4.62. The stock is currently 74.5% below its high.